Ironwood Pharmaceuticals | IRWD - Selling And Administration Expenses


Ironwood Pharmaceuticals reported $33.33M in Selling and Administration Expenses for its fiscal quarter ending in December of 2024.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 160.79M 14.06M Mar/2026
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Alnylam Pharmaceuticals USD 282.51M 2.55M Mar/2026
Amarin USD 18.97M 1.03M Dec/2025
Ardelyx USD 102.27M 26.35M Mar/2026
Astellas Pharma JPY 234.7B 12.92B Mar/2026
AstraZeneca USD 5.06B 455M Mar/2026
Charles River Laboratories USD 159.42M 36.71M Mar/2026
Coherus Biosciences USD 15M 6.26M Dec/2025
Emergent BioSolutions USD 182.8M 82.3M Jun/2023
Halozyme Therapeutics USD 46.29M 18.35M Mar/2026
Incyte USD 328.1M 62.31M Mar/2026
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
Karyopharm Therapeutics USD 9.56M 17.63M Dec/2025
Lexicon Pharmaceuticals USD 3.98M 195K Dec/2025
MacroGenics USD 9.71M 1.77M Mar/2026
Moderna USD 173M 135M Mar/2026
Myriad Genetics USD 122.3M 6.7M Dec/2025
Pacira USD 83.88M 7.99M Mar/2026
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
Takeda JPY 292B 9.21B Mar/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024